NAD+ levels drop 50% between age 20 and 60. Three main strategies exist to restore them: NAD+ IV infusions, NMN supplements, and NR supplements. A practical comparison of the evidence, costs, and trade-offs.
NAD+ is one of the most discussed molecules in longevity science — and one of the most confusing to supplement. The fundamental biology is not in dispute: NAD+ levels fall roughly 50% between age 20 and 60, and this decline is associated with mitochondrial dysfunction, reduced DNA repair capacity, impaired sirtuin activity, and accelerated cellular aging. The question is how to raise them effectively.
Three main approaches exist in 2026: NAD+ IV infusions (at longevity clinics), NMN (nicotinamide mononucleotide) supplements, and NR (nicotinamide riboside) supplements. They work through different biochemical pathways, have different bioavailability profiles, different costs, and different evidence bases. Here is a clear-eyed comparison.
NAD+ is a coenzyme required for hundreds of metabolic reactions. But its longevity relevance is primarily through three mechanisms:
Sirtuins: A family of seven protein deacylases (SIRT1–7) that regulate gene expression, DNA repair, inflammation, and metabolic adaptation. All seven sirtuins require NAD+ as a co-substrate. When NAD+ falls, sirtuin activity falls. David Sinclair's foundational research in this area established sirtuins as potential longevity regulators.
PARP enzymes: DNA repair proteins that consume large amounts of NAD+, especially in response to oxidative DNA damage. As we age and accumulate more DNA damage, PARP demand increases, further depleting NAD+. Supplementing NAD+ precursors can replenish the pool available for repair.
Mitochondrial function: The electron transport chain uses NAD+ and NADH in its redox cycling to generate ATP. Declining NAD+ reduces mitochondrial efficiency — a hallmark of aging muscle, brain, and heart tissue.
Direct NAD+ infusion bypasses the enzymatic steps required for precursor conversion and delivers NAD+ directly to circulation. Peak plasma NAD+ rises dramatically within the infusion period.
The case for IV: Highest and fastest plasma NAD+ elevation. Some users report an acute cognitive clarity effect during infusion (mechanism unclear). May be appropriate for individuals with impaired NAD+ biosynthesis enzymes.
The case against IV: NAD+ doesn't cross cell membranes directly — it must be broken down to NMN or NR, taken up by cells, and resynthesized. The peak elevation falls rapidly after infusion. The cells that most need higher NAD+ (muscle, brain) are not necessarily the ones best served by a 2-hour plasma peak. Cost is typically $200–600 per session. Evidence from RCTs is sparse.
Verdict: IV NAD+ is the most aggressive acute strategy but the evidence for superiority over sustained oral supplementation is thin. Useful for specific clinical scenarios; hard to justify as a routine longevity intervention given cost and evidence.
NMN is directly converted to NAD+ via a single enzyme step (NMNAT). It is taken up by cells via a dedicated transporter (Slc12a8 in mice; the human equivalent is still being characterized). Key human data:
NMN is available in capsule, powder, and sublingual forms. Sublingual NMN bypasses first-pass metabolism and may produce higher bioavailability peaks, though most published trials used oral capsule forms.
NR requires two enzymatic steps to become NAD+ (NR → NMN → NAD+ via NMNAT). Despite the extra step, it is the most studied oral NAD+ precursor in humans, with 8+ RCTs published.
No published randomized trial has directly compared NMN vs NR head-to-head in the same population using equivalent doses. The comparison is currently based on indirect evidence.
Blood NAD+ elevation: Both raise blood NAD+ meaningfully. NR studies show 40–60% elevation at 300–1000 mg/day; NMN studies show 38–60% at 250–1000 mg/day. Roughly comparable.
Muscle and tissue delivery: This is the key open question. Early data suggests NMN may have better muscle uptake via the Slc12a8-equivalent transporter. The muscle biopsy data from the NR trial was disappointing.
Cost: Both have come down significantly in price. NMN and NR products at therapeutic doses (500–1000 mg/day) are now available at $1–3/day.
Safety: Both have favorable safety profiles in published trials to date. No serious adverse events reported at doses up to 1000 mg/day in trials up to 12 weeks. Longer-term human data is still needed.
If you are choosing between NR and NMN: the evidence quality is higher for NR; the mechanistic case (direct uptake transporter, single enzymatic step) slightly favors NMN. Both are reasonable choices. Many practitioners use NMN at 500–1000 mg/day.
The more important variable is consistency. NAD+ precursors raise NAD+ levels while you take them; the elevation falls when you stop. This is a daily habit, not a one-time intervention. Start with a well-studied product, take it daily, and pair it with exercise (which independently raises NAD+ via AMPK activation) for synergistic effect.
NAD+ IV infusions are appropriate for specific clinical contexts. As a routine longevity strategy, the cost and evidence do not support them over consistent oral supplementation.